Title:
CRYSTAL FORM OF EMRACLIDINE, PREPARATION METHOD THEREFOR, AND USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2024/061253
Kind Code:
A1
Abstract:
The present invention relates to a crystal form of Emraclidine (hereinafter referred to as "compound I"), a preparation method therefor, a pharmaceutical composition containing the crystal form, and use of the crystal form in the preparation of an M4 receptor modulator medicament and a medicament for treating schizophrenia.
Inventors:
QIAN JIALE (CN)
HUANG CHUNXIANG (CN)
MENG LIPING (CN)
HUANG CHUNXIANG (CN)
MENG LIPING (CN)
Application Number:
PCT/CN2023/119900
Publication Date:
March 28, 2024
Filing Date:
September 20, 2023
Export Citation:
Assignee:
CRYSTAL PHARMACEUTICAL SUZHOU CO LTD (CN)
International Classes:
C07D471/04; A61K31/437; A61P25/18
Domestic Patent References:
| WO2022226078A1 | 2022-10-27 |
Foreign References:
| CN109641898A | 2019-04-16 |
Other References:
TSAPAKIS EVANGELIA MARIA, DIAKAKI KALLIOPI, MILIARAS APOSTOLOS, FOUNTOULAKIS KONSTANTINOS N.: "Novel Compounds in the Treatment of Schizophrenia—A Selective Review", BRAIN SCIENCES, MOLECULAR DIVERSITY PRESERVATION INTERNATIONAL (MDPI) AG., vol. 13, no. 8, 11 August 2023 (2023-08-11), pages 1193, XP093150094, ISSN: 2076-3425, DOI: 10.3390/brainsci13081193
Download PDF: